The experimental work of the Myeloma Lymphoma Research Programme includes a broad spectrum of research activity, where clinical haematologists from the Haemato-Oncology Unit and non-clinical researchers from Champalimaud Research work together to expand their knowledge of the biology of lymphoid neoplasms and their treatment.
Currently, we have several experimental research projects in collaboration with research groups including the Systems Oncology Group, the Computational Clinical Imaging Group and the Cancer Development and Innate Immune Evasion Group. These projects address questions such as mechanisms of progression of Multiple Myeloma, novel methods of evaluating bone disease, minimal residual disease in multiple myeloma and tailored therapy based on "in vitro" drug sensitivity evaluation.
We have received national funding through several research awards, including from the Fundação para a Ciência e a Tecnologia (FCT).
We are dedicated to clinical and translational research in the area of Haemato-Oncology, specifically in the area of Multiple Myeloma and Lymphoma. Our main objectives are to improve the diagnosis, immunophenotypic and molecular characterisation of these diseases, to study the patterns of therapeutic response to immunomodulatory agents and to improve high precision minimal residual disease protocols.
Translational Research, Liquid Biopsies, Rodents, Computational Algorithms and Gene Analysis
If you are interested in joining our group, please contact us at the email address bellow.